Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Published On: 2 June 2023

  • Flemingsberg Science leads ecosystem development with Stockholm Life Tech

    Within Stockholm Life Tech, we are currently working on developing the Life Science ecosystem at Campus Flemingsberg. And the first step in this process is a review of everything from academia to innovation support.

  • Applications for the Flemingsberg Science Award IDEA are now open

    Flemingsberg Science Award IDEA is an innovation competition for you who are students, living or working in Flemingsberg. In a sub-competition to the national business plan competition Venture Cup, Flemingsberg Science rewards ideas in the early stages - the prize sum is SEK 5,000.

  • DRIVE is looking for new startups – application deadline August 26

    In the incubator DRIVE, you can build your Life Science startup in a unique environment. Now they are looking for new startups and the deadline for applications is August 26.

  • Successful Kodkupan Flemingsberg pilot ahead of autumn term

    During the Kodkupan award evening in Flemingsberg, parents got to [...]

  • Hela wins Flemingsberg Science Award

    Hela is a company that is developing a mobile application that helps people with heart conditions improve their cardiac rehabilitation. The app encourages daily exercise, provides care support, and the ability to monitor progress.